ECM and Novilab to Commercialize Zecotek's 3D Auto-Stereoscopic Display Monitors in Russia and CIS Countries

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced its wholly owned subsidiary, Zecotek Display Systems Pte Ltd., has signed agreements with the Engineering Centre of the National Research Nuclear Center MEPhi (ECM) and its business affiliate Novilab Mobile LLC., to commercialize Zecotek's patented 3D auto-stereoscopic display monitors in Russia and countries of the Commonwealth of Independent States (CIS).

The agreements offer ECM and Novilab exclusive rights to the Russian 3D display market. In return ECM and Novilab will be responsible to fund the manufacturing technology transfer of the existing 3D display technology to a final product, and to commercialize the final product for specialized high-end markets in Russia.

"Novilab Mobile is affiliated to one of the most prominent and largest institutes in Russia, namely the Engineering Centre of the National Research Nuclear Center MEPhi (ECM), and together they have the capabilities to bring our 3D technology to the markets in Russian and CIS countries," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "This is a mutually beneficial partnership that will open larger opportunities for Zecotek's 3D technologies as a whole. Commercialization strategies for other parts of the world market are also in progress. The results of which will be announced upon finalization of agreements".

"The demand in Russia for such leading edge technology is substantial", said Andrey Starikovskiy, head of Novilab Mobile company. "We have identified specialized applications and customers for this new high speed, full high definition, multiple view capabilities offered by the Zecotek 3D display. Our plan is to market the initial designs to these high-end markets, where we will focus for the first 3 years of production. In parallel, we will work with our partners at Zecotek and ECM to complete the flat screen option for the larger consumer electronics end users in Russia and CIS countries."

"Zecotek's 3D display technology is truly unique in the world", said Dmitry Mikhaylov, Managing Director of ECM.  "We are delighted by the opportunity to take the present prototype to a commercial product."

As previously announced in Zecotek`s 3D Technology update released on July 6, 2015, the Company has been negotiating with a number of parties in an effort to bring the patented 3D display technology to the manufacturing stage. The ECM is part of the National Nuclear Research University of Russia and offers a proven ability to commercialize scientific technology with a number of well-defined applications of its own and an established high-end customer base. Earlier this year, a team from the ECM travelled to Zecotek`s 3D lab in Vancouver and conducted a thorough analysis of the 3D display technology. Impressed by the demonstration and the underlying technologies, the ECM moved to secure a contract and the two parties agreed to focus on existing industrial/governmental and marketing design customers in specialized high-end markets in Russia. The transfer of technology will begin immediately with initial sales of the 3D display monitors expect to start in the first quarter of 2016.

Zecotek`s patented, glasses free, 3D display system has significant competitive advantages compared to competing systems. It is based on the auto-stereoscopic principle, but with substantial innovative and patented improvements and represents a new and unique generation of 3D displays. It has the capability of simultaneously presenting 3D and 2D images on the same screen, and for separate views at different viewing angles. Zecotek's 3D display system requires no eyewear and has an effective viewing angle of 40 degrees with 90 concurrent perspectives allowing for multiple views at the same time. Another unique feature of the Zecotek system is constant motion parallax within the viewing angle. Motion parallax eliminates the sense of imbalance and dizziness during normal observation which can occur with polarized and shutter glasses used with other commercial systems.

Zecotek Display Systems is a wholly owned subsidiary of Zecotek Photonics. It owns a valuable portfolio of patented and patent pending 3D technologies. The main technologies include:

  1. Flat screen, front projection 3D auto-stereoscopic display,
  2. Large format, rear projection 3D auto-stereoscopic display,
  3. 3D printer technology,
  4. New material alloys and semiconducting for 3D printing,
  5. Accompanying interfaces for all 3D technologies.

The 3D patent portfolio includes allowances from the United States, China, Europe, Eurasia, Russia and Australia. Other patents have been filed and are pending in Japan, Korea and India.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Zecotek Photonics. (2019, February 25). ECM and Novilab to Commercialize Zecotek's 3D Auto-Stereoscopic Display Monitors in Russia and CIS Countries. AZoOptics. Retrieved on December 08, 2024 from https://www.azooptics.com/News.aspx?newsID=21358.

  • MLA

    Zecotek Photonics. "ECM and Novilab to Commercialize Zecotek's 3D Auto-Stereoscopic Display Monitors in Russia and CIS Countries". AZoOptics. 08 December 2024. <https://www.azooptics.com/News.aspx?newsID=21358>.

  • Chicago

    Zecotek Photonics. "ECM and Novilab to Commercialize Zecotek's 3D Auto-Stereoscopic Display Monitors in Russia and CIS Countries". AZoOptics. https://www.azooptics.com/News.aspx?newsID=21358. (accessed December 08, 2024).

  • Harvard

    Zecotek Photonics. 2019. ECM and Novilab to Commercialize Zecotek's 3D Auto-Stereoscopic Display Monitors in Russia and CIS Countries. AZoOptics, viewed 08 December 2024, https://www.azooptics.com/News.aspx?newsID=21358.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.